Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 4Phase 3 3Phase NA 2Phase 1/2 2Phase 4 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 149Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Large B-Cell, Diffuse 46Leukemia 44Lymphoma, Follicular 39Lymphoma, Non-Hodgkin 35Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia, Myeloid, Acute 25Burkitt Lymphoma 24Neuroblastoma 21Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Lymphoma, Mantle-Cell 14Neoplasms 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 11Sarcoma 10Inflammatory Breast Neoplasms 10Rhabdomyosarcoma 8Recurrence 8Neoplasms, Plasma Cell 8Myelodysplastic Syndromes 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Graft vs Host Disease 8Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Biphenotypic, Acute 7Lung Neoplasms 6

Interventions

Melphalan 8Dexamethasone 7Bortezomib 6Filgrastim 4Cyclophosphamide 3liposomal amphotericin B 2Early Intervention, Educational 2Darbepoetin alfa 2Clinical Protocols 2Calcium Dobesilate 2ferrous sulfate 1ferric gluconate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1birtamimab 1auricularum 1Sucrose 1Stem Cell Transplantation 1Specimen Handling 1Pharmacogenomic Testing 1Peripheral Blood Stem Cell Transplantation 1Ondansetron 1Morphine 1Magnetic Resonance Spectroscopy 1Ketamine 1Hypericum extract LI 160 1Granulocyte Colony-Stimulating Factor 1Fentanyl 1Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Immunoglobulin Light-chain Amyloidosis × Cyclophosphamide × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
281 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

Alexion Pharmaceuticals, Inc.

Phase 3 Active not recruiting
125 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡